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INTRODUCTION
Gastrointestinal stromal tumors (GISTs) originate
from mesenchymal cells of the gastrointestinal tract.
They were previously designated as smooth muscle
tumors, either leiomyoma or leiomyosarcoma. These
tumors occur predominantly in middle-aged or older
persons. Seventy percent are found in the stomach,
20% to 30% in the small intestine, and less than
10% elsewhere in the gastrointestinal tract [1]. The
relationship between GISTs and activation of the
cell surface transmembrane KIT tyrosine kinase
receptor has been well established [2, 3]. Imatinib
mesylate (Gleevec®, Novartis) inhibits the KIT signal
transduction pathway and has yielded a sustained
objective response in half of patients with un-
resectable or metastatic GISTs [4]. Computed tomo-
graphy (CT), magnetic resonance imaging (MRI),
and positron emission tomography have all been
used to follow treatment response. However, they
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Metastatic gastrointestinal stromal tumor (GIST) is a high-grade malignancy with
a poor prognosis. In recent years, the relationship between GISTs and activation
of the cell surface transmembrane receptor KIT has been well established. Imatinib
mesylate inhibits the KIT signal transduction pathway, yielding a good response
in half of patients with metastatic or unresectable GISTs. We report a patient with
GIST hepatic metastases treated with imatinib mesylate. Cystic changes in the
metastatic tumors were found on both computed tomography (CT) and sonography.
While both CT scan and sonography showed changes in response to treatment,
sonography demonstrated some features that CT did not, such as the change in wall
thickness, mural nodules, and fluid-fluid levels. However, CT scan after contrast
showed tumor viability and provided an overview of the lesions that sonography
did not. We discuss the sonographic features of GISTs treated with imatinib mesylate
and compare the findings with CT scan.
(J Med Ultrasound 2003;11:7–12)
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are expensive and are not always readily available.
Because hepatitis B and hepatocellular carcinoma
are endemic in Taiwan, we have considerable
experience with abdominal ultrasonography, including
its use in the evaluation of hepatic metastases. We
report a Taiwanese patient with GIST metastatic to
the liver who was treated with imatinib mesylate.
The ultrasonographic features are discussed and
correlated with CT findings. To our knowledge, this
is the first report of the ultrasonographic features
of GIST hepatic metastases treated with imatinib
mesylate.
CASE REPORT
In May 2001, a 57-year-old female presented with
abdominal discomfort and poor appetite for 1 month.
A palpable mass in the lower abdomen was found
several days prior to admission. She visited the
surgical outpatient department of Mackay Memorial
Hospital where abdominal CT revealed an intra-
abdominal tumor originating from the small intestine.
At laparotomy, an 18 = 20 cm mass was found in
the small intestine 80 cm from the ligament of
Treitz. The tumor and surrounding omentum and
peritoneum were resected. Frozen sections revealed
a malignant stromal cell tumor of the jejunum with
peritoneal seeding. Histologically, sections showed
a tumor arising from the muscularis propria of the
jejunum, composed of solid growth of elongated
oval to spindle neoplastic cells with a mitotic count
of more than 10 per 10 high power fields. Tumor
cells stained with S100 were focally positive for
neuron-specific enolase, and negative for actin
and desmin. The diagnosis of GIST was confirmed
by immunostaining with CD117. In addition, a
c-kit mutation with an insertion in exon 9 was
detected.
In January 2002, a small, ill-defined, hypoechoic
hepatic tumor (14 = 13 mm) was found on abdominal
sonography and CT. No mass lesion was seen
elsewhere in the abdomen. Echo-guided fine needle
aspiration yielded groups of spindle cells, diagnosed
as a metastatic tumor. The patient underwent
percutaneous ethanol intratumor injection. She was
lost to follow-up after the procedure.
In August 2002, the patient visited the oncology
outpatient department complaining of abdominal
fullness, poor appetite, and a reported 5 kg weight
loss in 6 months. Repeat abdominal sonography
revealed two solid intra-abdominal masses, five large
hepatic lesions around 5 cm in diameter, and a small
2 cm hepatic lesion in the right lobe of the liver.
Some of the hepatic lesions had ill-defined margins
on sonography. One large hepatic lesion and a small
lesion were hypoechoic with nearly homogeneous
parenchyma. The other hepatic lesions were
hypoechoic with a heterogeneous parenchyma and
central sonolucent component. The margin between
the central sonolucent area and the tumor was
irregular and some echogenic material was found
inside the sonolucent component. The intra-abdominal
lesions were well defined with a homogeneous
parenchyma (Fig. 1).
The diagnosis was recurrent GIST, and systemic
chemotherapy or imatinib mesylate treatment was
recommended. However, the patient was hesitant
to undergo additional treatment at that time.
Subsequently, her abdominal discomfort increased,
and CT revealed progression of the lesions (Fig. 2).
Therefore, imatinib mesylate, 400 mg/day, was given
from October 11, 2002. The dose was based on a
study of the safety and tolerability of imatinib
mesylate for GIST [5]. The response to treatment
was evaluated monthly by means of abdominal
sonography and CT.
After 4 weeks of treatment, the abdominal
discomfort improved and the patient denied any
other discomfort except for ankle edema. On
abdominal sonography, cyst-like changes with a thick
wall and well-defined margin were found in three
of the five large tumors. One tumor became more
well defined with a central sonolucent component,
and another tumor became hyperechoic with a small
central sonolucent component. The tumor size was
only slightly decreased in comparison to previous
sonography (Fig. 3). On CT, near-cystic changes
were found in four lesions before intravenous contrast
media and one lesion remained cyst-like without a
thickened wall after contrast. No hyperdense
component or fluid-fluid level was found on CT
images (Fig. 4).
After 8 weeks of treatment, sonography revealed
that all the tumors except one had become cyst-
like with thick walls. Some of the lesions had
fluid-fluid levels and mural nodules. The thick-
ness of the tumor walls decreased and the margin
between the tumors and liver parenchyma became
clear. The previously hyperechoic lesion was
unchanged after treatment (Fig. 5). On CT scan, the
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tumors were slightly smaller in size compared to
previous CT scan; otherwise, the CT images were
almost the same as the scans taken after 4 weeks
of treatment (Fig. 6).
After 8 weeks of treatment, the patient dis-
continued imatinib mesylate therapy because she
could no longer afford it. However, follow-up
continues.
Fig. 2. Abdominal computed tomography before treatment with imatinib mesylate. (A) Before intravenous contrast
medium infusion, all hepatic metastases are hypodense with homogeneous parenchyma, except for a small central
darkness in two tumors (arrows). (B) After contrast, the tumors are slightly enhanced (broad arrow) and the central
hypodense areas are augmented (thin arrows).
BA
DISCUSSION
GISTs are specific KIT-expressing and KIT-signaling-
driven mesenchymal tumors [2]. They can range
from small benign tumors to sarcomas with a high
metastatic potential [6]. The prognosis depends on
tumor stage at presentation (peritoneal or liver
metastases confer a poor prognosis), tumor site
Fig. 1. Abdominal sonography before treatment with imatinib mesylate. (A) Some metastatic tumors are ill defined
with homogeneous parenchyma (thin arrow), and one has a heterogeneous parenchyma and central sonolucent
component. The margin between the central sonolucent area and the tumor is irregular (broad arrow). (B) Some
echogenic material is found inside the sonolucent component (curved arrow). (C) Intra-abdominal tumors are well
defined with nearly homogeneous parenchyma (arrows).
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(tumors of the stomach and rectum are often small
and have low potential for malignancy, while those
in the small intestine and colon are often advanced
sarcomas), tumor size and mitotic activity (in
intestinal tumors, a diameter of less than 2 cm and
fewer mitoses than five per 50 high power fields,
and in stomach tumors, a diameter of less than
5 cm and fewer mitoses than five per 50 high power
fields probably indicate benign tumors), cellularity
and nuclear atypia (low cellularity is a favorable
prognostic factor), muscle and mucosal invasion,
and immunohistochemical differentiation markers [7].
Surgical resection is believed to be the only cure
for GISTs [8]. However, in patients with high-grade
Fig. 3. Abdominal sonography after 4 weeks of treatment
with imatinib mesylate. (A) Cyst-like changes with a thick
wall and well-defined margin are found. The margin
between the central sonolucent component and the tumor
is smooth (arrow). Fluid-fluid level is present (curved
arrow). (B) One tumor is hyperechoic with a small central
sonolucent component (arrow). Another tumor is more
well defined with a central sonolucent component (curved
arrow) compared to previous sonography (Fig. 1A, thin
arrow). (C) Cyst-like tumor with mural nodule (arrow)
and fluid-fluid level (curved arrow) were noted.
Fig. 4. Abdominal computed tomography after 4 weeks
of treatment. (A) Before contrast, there is near-cystic
change in all lesions (arrows). Wall thickness can hardly
be seen in some tumors (curved arrows). (B) After contrast,
one lesion remains cyst-like without wall thickness (thin
arrow). Slightly enhanced thick walls are found in the
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GISTs with multiple metastases, such as in our
patient, complete surgical resection is impossible.
Imatinib mesylate provides hope for sustained
remission of disseminated disease. Traditionally, the
response to treatment has been evaluated by CT.
Chen et al reported near-cystic changes in hepatic
metastases treated with imatinib mesylate; the only
difference from a true cyst was that it had a slightly
higher CT number [9]. In comparison to the CT
image, sonography revealed a fluid-fluid level and
mural nodules in the cyst-like lesion. The wall
thickness demonstrated on sonography differentiates
the lesions from true cysts and can be measured
easily to monitor response to treatment, which is not
possible with CT even after contrast. Sonography
in this case demonstrated morphologic features that
were not readily apparent on CT. The CT image
was essentially unchanged from 4 weeks to 8 weeks
after treatment, while sonography showed definite
evolution of the lesions during this period, including
the fluid-fluid level, mural nodules, and wall thickness
changes. However, CT images provided an overview
of the lesions and enhanced CT was helpful in
demonstrating tumor viability. In clinical practice,
sonography is non-invasive and inexpensive and does
not need infusion of contrast medium. Since the
evolution of tumors during treatment is significant
on sonography, frequent evaluation using abdominal
sonography followed by CT scan every 3 to 6 months
may be adequate.
The mechanism inducing cystic change after
treatment with imatinib mesylate is uncertain. To our
knowledge, the changes on imaging studies are not
found with traditional cytotoxic chemotherapy or
radiation therapy. It may be that inhibition of KIT-
signaling transduction induces tumor apoptosis. In
Fig. 5. Abdominal sonography after 8 weeks of treatment.
(A) The tumor wall is thinner (curved arrow) than on
previous sonography (Fig. 3A, arrow) and a mural nodule
is present (arrow). (B) One lesion remains hyperechoic
without cystic change (arrow).
Fig. 6. Computed tomography (CT) with (A) and without
(B) contrast after 8 weeks of treatment shows that the
tumors are slightly smaller than on CT images 1 month
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a large-scale study by Demetri et al [4], patients
responding to imatinib mesylate therapy had no
hyperuricemia, i.e. no evidence of tumor lysis
syndrome. This supports the hypothesis of treatment-
induced apoptosis rather than necrosis. In our patient,
one metastatic tumor did not appear to respond to
treatment. This diversity of treatment response merits
further study.
SUMMARY
We found that in a patient with GIST hepatic
metastases treated with imatinib mesylate, sonography
was superior to CT in differentiating cyst-like lesions
from simple cysts and monitoring the response to
treatment. Wall thickness, mural nodules, and a
fluid-fluid level were distinguishing features on
sonography. Further experience with other patients
followed for longer periods will be required to
confirm our results. However, this case suggests that
sonography is worth further investigation as a tool
for following the response to imatinib mesylate
treatment of GIST hepatic metastases.
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